Advertisement

Topics

Clinical Trials About "Tumor Marker Testing Analyzers Reagents Market 2021 Supplier" RSS

05:34 EDT 18th October 2017 | BioPortfolio

We list hundreds of Clinical Trials about "Tumor Marker Testing Analyzers Reagents Market 2021 Supplier" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Tumor Marker Testing Analyzers Reagents Market 2021 Supplier" on BioPortfolio

We have published hundreds of Tumor Marker Testing Analyzers Reagents Market 2021 Supplier news stories on BioPortfolio along with dozens of Tumor Marker Testing Analyzers Reagents Market 2021 Supplier Clinical Trials and PubMed Articles about Tumor Marker Testing Analyzers Reagents Market 2021 Supplier for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tumor Marker Testing Analyzers Reagents Market 2021 Supplier Companies in our database. You can also find out about relevant Tumor Marker Testing Analyzers Reagents Market 2021 Supplier Drugs and Medications on this site too.

Showing "Tumor Marker Testing Analyzers Reagents Market 2021 Supplier" Clinical Trials 1–25 of 12,000+

Extremely Relevant

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B

This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the safety, pharmacokinetics (how the trial drug is distributed in the body) and pharmacodynamics (physiological effects of the drug on the body) of NNC 0172-0000-2021 administered intravenously and subcutaneously to healthy male subjects and subjects with haemophilia A or B


Relevant

Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors

This study aimed to evaluate serum thymidine kinase 1 (TK1) activity as a marker for solid tumors and more specifically in: preoperative testing for prediction of disease recurrence and survival; follow-up after surgical removal of the original tumor for early detection of disease recurrence and in monitoring therapy as a surrogate marker of tumor response.

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients


Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC

Evaluation of individual peripheral blood circulating tumor cells combined with tumor marker detection of efficacy of chemotherapy in patients with advanced colorectal cancer: A observational clinical trial

Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the pseudo-progression after radiochemotherapy, the radionecrosis, the diagnosis of the relapse and the follow-up under anti-angiogenic can pose problems Clinicians and radiologists. Accessibility to a plasma tumor molecular marker would greatly facilitate th...

Comparison of On-line and Off-line Measurements of Exhaled Nitric Oxide (NO)

Asthma is a major health problem worldwide. The measurement of fractional exhaled nitric oxide (FENO) has been established as a valuable non invasive and simple tool in the diagnosis of asthma and may also act as a useful surrogate inflammatory marker on which to base treatment decisions in asthma management algorithms. The measurement is useful also in other respiratory diseases. Current methods of measuring FENO include on line measurements by heavy duty expensive analyzers w...

Observational, Non-Interventional, Prospective, Post Market Surveillance & Post Market Clinical Follow up, International, Medical Registry to Confirm the Safety and the Performance of the Anecova Intra Uterine Culture Device

This study is designed to generate a comprehensive survey of the use on the market of the Anecova device within its intended indications according to the Instructions For Use. The Anecova Registry is part of the Anecova quality system, to enable the Post Marketing Surveillance and the Post Market Clinical Follow-up.

Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.

Differences in Coagulation Test Kits

The aim of this study is to assess the effect of Innovin® reagent on laboratory results when compared with the Thromborel® S.

Mesothelin as a New Tumor Marker for Ovarian Cancer

Ovarian cancer became a more and more important disease in recent years due to its first mortality rate of gynecologic malignancies. The incidence of ovarian cancer also increased in recent year in Taiwan. The lack of symptoms, difficulties in early diagnosis, insufficient accurate tumor markers, and lack of information about ovarian tumor biology contribute to the poor prognosis in ovarian cancer patients. The prognostic parameters for ovarian carcinomas are tumor stage, histo...

Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment

This study will evaluate the usefulness of plasma proteasome levels as a tumor marker of hepatocellular carcinoma (HCC) by studying their variation following curative treatment of HCC. The hypothesis of the study is that plasma proteasome levels will decrease following curative treatment, and that proteasome levels could be used as a marker to detect early recurrence.

p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer

Study Hypothesis: PANCHO is a prospective randomized, predictive marker study, evaluating the interaction between the potential predictive marker 'p53 genotype' and response to induction chemotherapy in patients with esophageal cancer considered resectable. 170 patients with measurable disease will be enrolled in this study. After testing the marker genotype (two genotypes: p53 normal or p53 mutant) patients will be stratified according to histological subtype only (ade...

Magseed and Sentimag in Surgical Excision of Breast Lesions

The goal of this clinical research study is to learn more about the safety and effectiveness of a marker called Magseed that is used to help locate lesions during surgery. The Magseed marker is a small metallic marker (smaller than a grain of rice) that is placed in participant's breast close to or inside the lesion by participant's radiologist.

Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer

The investigators will compare tumor marker levels, including PSA, in samples taken from a peripheral upper limb vein and the internal iliac veins. These will be collected from patients who are scheduled for prostatectomy as part of their standard of care for prostate cancer. A selective internal iliac vein sampling procedure will be performed in Interventional Radiology. Venous samples will be correlated with prostatectomy specimens. The aim is to predict the side of the prost...

Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device

This study is a post-market clinical follow-up study. A post-market, prospective clinical trial will be conducted. The data collected from this study will serve the purpose of confirming safety and performance of the FLXfit™ implant.

Epicutaneous Testing of Cosmetics

The dermatological testing of cosmetic products which are new on the market, or existing products with novel formulations is common and a useful procedure, yet necessary to alleviate common irritants and contact allergic reactions. Cosmetic products contain a range of substances that may be considered as potential irritants or contact allergens. In order to estimate that risk, cosmetics are tested by applying patch tests.

Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy

About 30% of breast cancers have higher than normal levels of a cellular marker called HER2. The amount of HER2 is often measured in breast tissue. A higher level of this marker usually indicates a more aggressive type of breast cancer. Cytokeratin is a second cellular marker found in breast cancer cells. Detection of Circulating cytokeratin in the blood could indicate the presence of cancer. The Pathology Department of the Tom Baker Cancer Center is doing this study to se...

Capillary and Venous Lactate in Emergency Department Patients

The objective of the present project is to study the accuracy of capillary blood level measured by handheld lactate analyzers when compared with the reference methods e.g.venepuncture blood gas analyzer sample.

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.

Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region

Severe malaria and bacterial Blood Stream Infections (bBSI) are impossible to differentiate clinically. This poses a particular threat in low resource areas, where bBSI is often not diagnosed due to the unavailability of rapid diagnostic means. Even if used appropriately, the sensitivity of blood culture to diagnose bBSI is estimated to be around 50%. To counter the high mortality rate associated with bBSI, antibiotics are often prescribed without microbiological confirmation. ...

Tumor Marker Levels in Biopsy Specimens From Current or Former Smokers With Bronchial Dysplasia Treated With Inositol

RATIONALE: Studying samples of tissue in the laboratory from patients with bronchial dysplasia receiving inositol may help doctors understand the effect of inositol on biomarkers. PURPOSE: This phase I trial is studying tumor marker levels in biopsy specimens from current or former smokers with bronchial dysplasia treated with inositol.

Study the Use of Magseed and Sentimag to Localize Axillary Lymph Nodes

The goal of this clinical research study is to learn more about the safety and effectiveness of a marker called Magseed that is used to help participant's doctor locate lymph nodes that contain cancer under participant's arm during surgery. The Magseed marker is a small metallic marker (smaller than a grain of rice) which is placed in or near the lymph node by participant's radiologist.

Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer

Primary Outcome Measures: Disease free survival Secondary Outcome Measures: Overall survival Adverse events (Mortality, morbidity) The proportion of completion of Laparoscopic Surgery Estimated Enrollment: Oct, 2016 Study Start Date: Oct, 2016 Estimated Study Completion Date: Oct, 2019 Estimated Primary Completion Date: Oct, 2021 Groups/Cohorts 1. Laparoscopic surgery for T4 colon cancers 2. Neoadjuvantive chemotherapy + Laparo...

Zenith® TXD Post-market Surveillance in Japan

The study is a post-market surveillance study required by Japanese Regulatory Authorities as a condition of approval

Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM)

Currently, chemotherapies are empirically administered to patients treated for colorectal cancer (CRC). Selection is based on the efficacy of a protocol previously determined on the largest number (consensus treatment), the decision-making process being weighted by patient's intrinsic criteria. However, each patient is unique, due to the inter- and intratumoral heterogeneity inherent in any cancer, partly explaining the unsatisfactory response rates observed for available chemo...


More From BioPortfolio on "Tumor Marker Testing Analyzers Reagents Market 2021 Supplier"

Quick Search
Advertisement